Cover Image
市場調查報告書

視神經脊髓炎 (戴維克症候群):開發中產品分析

Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 293889
出版日期 內容資訊 英文 98 Pages
訂單完成後即時交付
價格
Back to Top
視神經脊髓炎 (戴維克症候群):開發中產品分析 Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2016
出版日期: 2016年09月14日 內容資訊: 英文 98 Pages
簡介

以戴維克症候群知名的視神經脊髓炎 (NMO) 是腦,脊髓,神經由於疾病或受傷所引起的罕見神經病變,或是自體免疫系統異常反應,攻擊了體內細胞和組織的自體免疫疾病。也有免疫系統攻擊髓鞘的病例。症狀有失明,四肢無力感,麻痺,腸及膀胱問題等。

本報告網羅全球視神經脊髓炎治療藥的開發平台資訊,提供您目前開發平台狀況和最新趨勢,藥物簡介,主要企業及開發中的產品檢討等資訊,為您概述為以下內容。

簡介

  • 調查範圍

視神經脊髓炎 (戴維克症候群) 概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

視神經脊髓炎:正在開發的治療藥:各企業

視神經脊髓炎:正在開發的治療藥:大學·研究機關別

視神經脊髓炎:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

視神經脊髓炎:開發中的產品:各企業

視神經脊髓炎:開發中的產品:大學·研究機關別

視神經脊髓炎:治療藥的開發企業

  • Acorda Therapeutics, Inc.
  • Alexion Pharmaceuticals, Inc.
  • 中外製藥
  • Genmab A/S
  • HanAll Biopharma Co., Ltd.
  • Karus Therapeutics Limited
  • MedImmune, LLC
  • Opexa Therapeutics, Inc.
  • Shire Plc
  • 武田藥品工業

視神經脊髓炎:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • C1 esterase inhibitor (human)
  • dalfampridine ER
  • Dendritic Cell Therapy for Central Nervous System Disorders
  • Drugs to Inhibit Neutrophil Elastase for Neuromyelitis Optica
  • eculizumab
  • HL-161
  • immune globulin (human)
  • KA-1463
  • MEDI-551
  • ofatumumab
  • OPX-212
  • SA-237
    • 產品概要
    • 作用機制
    • R&D的進展

視神經脊髓炎:最近的開發平台趨勢

視神經脊髓炎:暫停中的計劃

視神經脊髓炎:產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8445IDB

Summary

Global Markets Direct's, 'Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2016', provides an overview of the Neuromyelitis Optica (Devic's Syndrome) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neuromyelitis Optica (Devic's Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuromyelitis Optica (Devic's Syndrome) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Neuromyelitis Optica (Devic's Syndrome)
  • The report reviews pipeline therapeutics for Neuromyelitis Optica (Devic's Syndrome) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Neuromyelitis Optica (Devic's Syndrome) therapeutics and enlists all their major and minor projects
  • The report assesses Neuromyelitis Optica (Devic's Syndrome) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Neuromyelitis Optica (Devic's Syndrome)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Neuromyelitis Optica (Devic's Syndrome)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Neuromyelitis Optica (Devic's Syndrome) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Neuromyelitis Optica (Devic's Syndrome) Overview
  • Therapeutics Development
    • Pipeline Products for Neuromyelitis Optica (Devic's Syndrome) - Overview
    • Pipeline Products for Neuromyelitis Optica (Devic's Syndrome) - Comparative Analysis
  • Neuromyelitis Optica (Devic's Syndrome) - Therapeutics under Development by Companies
  • Neuromyelitis Optica (Devic's Syndrome) - Therapeutics under Investigation by Universities/Institutes
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Neuromyelitis Optica (Devic's Syndrome) - Products under Development by Companies
  • Neuromyelitis Optica (Devic's Syndrome) - Products under Investigation by Universities/Institutes
  • Neuromyelitis Optica (Devic's Syndrome) - Companies Involved in Therapeutics Development
    • Acorda Therapeutics, Inc.
    • Alexion Pharmaceuticals Inc
    • Biogen Inc
    • Bionure Farma, S.L.
    • Chugai Pharmaceutical Co., Ltd.
    • Clene Nanomedicine, Inc.
    • HanAll Biopharma Co., Ltd.
    • Karus Therapeutics Limited
    • LFB S.A.
    • Marathon Pharmaceuticals, LLC
    • MedImmune, LLC
    • Opexa Therapeutics, Inc.
    • Shire Plc
    • Takeda Pharmaceutical Company Limited
  • Neuromyelitis Optica (Devic's Syndrome) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • ANV-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • BN-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • C1 esterase inhibitor (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Central Nervous System Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • cladribine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CNMAU-8 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • D-15107 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dalfampridine ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • eculizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HL-161 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • inebilizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KA-1463 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OPX-212 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Enzyme to Inhibit IgG for Neuromyelitis Optica - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rituximab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SA-237 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Neuromyelitis Optica - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ublituximab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Neuromyelitis Optica (Devic's Syndrome) - Dormant Projects
  • Neuromyelitis Optica (Devic's Syndrome) - Product Development Milestones
    • Featured News & Press Releases
      • Aug 26, 2016: TG Therapeutics Announces Orphan Drug Designation for TG-1101 for the Treatment of Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder
      • Nov 24, 2015: MS Trial Alert: Investigators Recruiting People with Relapsing NMOSD for Study of an Investigational Medicine (Eculizumab)
      • Nov 10, 2015: Opexa Therapeutics Announces Supportive Preclinical Study Results for its Neuromyelitis Optica Program
      • Sep 29, 2015: FDA Approval To Commence Phase I Single Ascending Dose Protocol
      • May 08, 2015: Initiation Of Phase I Clinical Program
      • Apr 20, 2015: Opexa Therapeutics Invited to Present Biomarker Data from NMO Patients at The American Academy of Neurology 2015 Annual Meeting
      • Apr 15, 2015: Clene Receives IMPD Approval; Phase I Clinical Program Planned
      • Nov 25, 2014: Soliris (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Neuromyelitis Optica
      • Sep 08, 2014: Opexa Therapeutics to Target Rare Disease Neuromyelitis Optica as next Development Program
      • Aug 27, 2014: Clene Files Investigational New Drug Application With FDA
      • Apr 24, 2014: Alexion Initiates Multinational Registration Trials of Eculizumab as a Potential Treatment for Patients with Relapsing Neuromyelitis Optica and Refractory Generalized Myasthenia Gravis
      • Apr 01, 2014: Clene Nanomedicine Requests Pre-IND Meeting With FDA
      • Dec 16, 2013: Soliris Concentrated Solution for Intravenous Infusion by Alexion: Recall - Visible Particles
      • Dec 13, 2013: Alexion Provides Update on Previously Communicated November 2013 Voluntary Nationwide Recall of Two Lots of Soliris Concentrated Solution for Intravenous Infusion
      • Jul 16, 2013: Alexion's Soliris Receives Positive Opinion from the Committee for Orphan Medicinal Products for Treatment of Neuromyelitis Optica
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Neuromyelitis Optica (Devic's Syndrome), H2 2016
  • Number of Products under Development for Neuromyelitis Optica (Devic's Syndrome) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Acorda Therapeutics, Inc., H2 2016
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Alexion Pharmaceuticals Inc, H2 2016
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Biogen Inc, H2 2016
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Bionure Farma, S.L., H2 2016
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2016
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Clene Nanomedicine, Inc., H2 2016
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline by HanAll Biopharma Co., Ltd., H2 2016
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Karus Therapeutics Limited, H2 2016
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline by LFB S.A., H2 2016
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Marathon Pharmaceuticals, LLC, H2 2016
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline by MedImmune, LLC, H2 2016
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Opexa Therapeutics, Inc., H2 2016
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Shire Plc, H2 2016
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Neuromyelitis Optica (Devic's Syndrome) - Dormant Projects, H2 2016

List of Figures

  • Number of Products under Development for Neuromyelitis Optica (Devic's Syndrome), H2 2016
  • Number of Products under Development for Neuromyelitis Optica (Devic's Syndrome) - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top